Brentuximab vedotin|914088-09-8|(维布妥昔单抗；本妥昔单抗)-陌孚医药/Medlife

您当前的位置：

Brentuximab vedotin (Synonyms: 维布妥昔单抗；本妥昔单抗)

目录号: PL11937 纯度: ≥98%

CAS No. :914088-09-8

商品编号	规格	价格	会员价
PL11937-1mg	1mg	¥6181.82	请登录
PL11937-5mg	5mg	¥15454.55	请登录
PL11937-10mg	10mg	询价	询价
PL11937-50mg	50mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Brentuximab vedotin
中文别名	本妥昔单抗;维布妥昔单抗
英文名称	Brentuximab vedotin
英文别名	Brentuximab;Brentuximab Vedotin;Anti-CLDN18.2;Anti NS1 of dengue virus;Moxetumomab;Research Grade Brentuximab(DHD80901);Brentuximab vedotin
Cas No.	914088-09-8
包装储存	Please store the product under the recommended conditions in the Certificate of Analysis.

产品详情

Brentuximab vedotin (cAC10-vcMMAE) 是一种抗体-药物偶联物 (ADC)，由抗 CD30 抗体和 Monomethyl auristatin E (MMAE) 组成。Brentuximab vedotin 抑制 CD30 阳性细胞，其 IC₅₀ 值为 2.5 ng/mL。Brentuximab vedotin 可用于复发难治性霍奇金淋巴瘤的研究。

生物活性

Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC 50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.

性状

Solid

IC50 & Target[1][2]

IC50: 2.5 ng/mL (CD30)

体外研究(In Vitro)

Brentuximab vedotin (cAC10-vcMMAE) (1 μg/mL; 96 h) shows cytotoxicity to CD30 in Karpas 299 cells.
Brentuximab vedotin (CAC10-VCMMAE) (1 μg/mL; 12, 24 and 48 h) selectively induces growth arrest in G2/M phase then lead to apoptotic cell death.
has not independently confirmed the accuracy of these methods. They are for reference only.Cell Cytotoxicity Assay

体内研究(In Vivo)

Brentuximab vedotin (cAC10-vcMMAE) (10-120 mg/kg; i.p. for 3 weeks) the maximum tolerated dose (MTD) is between 30 and 40 mg/kg.
Brentuximab vedotin (cAC10-vcMMAE) (0.3, 1 mg/kg; flanks injection; every 4 days for a total of 4 doses 1 mg/kg) induces tumor CD30 regression. has not independently confirmed the accuracy of these methods. They are for reference only.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

ClinicalTrial

参考文献

[1]. Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr Hematol Malig Rep. 2020 Feb;15(1):9-19.
[2]. Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65.

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation